Chemotherapeutic implants via subcritical CO2 modification

Biomaterials

Volumn 28, Issue 36, 2007, Pages 5562-5569

  Powell, Heather M ^a   Ayodeji, Olukemi ^a   Summerfield, Taryn L ^a,b   Powell, David M ^b   Kniss, Douglas A ^b   Tomasko, David L ^a   Lannutti, John J ^a  

^a The Ohio State University   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; Controlled drug release; Degradation; In vitro test; Polylactic acid

Indexed keywords

CARBON DIOXIDE; CHEMOTHERAPY; MEDICINE; POLYMERS; TISSUE;

CHEMOTHERAPEUTIC IMPLANTS; CONTROLLED DRUG RELEASE; POLYLACTIC ACID; POLYMERIC SURFACE;

BIOMATERIALS;

CARBON DIOXIDE; PACLITAXEL; POLYLACTIC ACID; POLYMER;

ARTICLE; CANCER CELL CULTURE; CANCER SURGERY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMPLANT; OSTEOSYNTHESIS; PRIORITY JOURNAL;

APOPTOSIS; CARBON DIOXIDE; CELL LINE, TUMOR; HUMANS; MICROSCOPY, ELECTRON, SCANNING; PROSTHESES AND IMPLANTS;

EID: 35349031666     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2007.09.004     Document Type: Article

References (54)

1. Hunter W.L., Burt H.M., and Machan L. Local delivery of chemotherapy: a supplement to existing cancer treatments; a case for surgical pastes and coated stents. Adv Drug Delivery Rev 26 (1997) 199-207
2. Kleinberg L, Knisely JPS, Heitmiller R, Zahurak M, Salem R, Burtness B, et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. 2003;56(2):328-34.
3. Thomasin C., Johansen P., Alder R., Bemsel R., Hottinger G., Altorfer H., et al. A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation. Eur J Pharm Biopharm 42 1 (1996) 16-24
4. Burt H.M., Jackson J.K., Bains S.K., Liggins R.T., Oktaba A.M.C., Arsenault A.L., et al. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). Cancer Lett 88 1 (1995) 73-79
5. Bitz C., and Doelker E. Influence of the preparation method on residual solvents in biodegradable microspheres. Int J Pharmaceut 131 (1996) 171-181
6. Sproule T.L., Lee J.A., Li H., Lannutti J.J., and Tomasko D.L. Bioactive polymer surfaces via supercritical fluids. J Supercritical Fluids 28 (2004) 241-248
7. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int J Pharmaceut 172 1-2 (1998) 1-15
8. Pillai O., Dhanikula A.B., and Panchagnula R. Drug delivery: an odyssey of 100 years. Curr Opin Chem Biol 5 4 (2001) 439-446
9. Dhanikula A.B., and Panchagnula R. Localized paclitaxel delivery. Int J Pharmaceut 183 2 (1999) 85-100
10. Singla A.K., Garg A., and Aggarwal D. Paclitaxel and its formulations. Int J Pharmaceut 235 1-2 (2002) 179-192
11. Zuylen L.v., Verweij J., and Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19 (2001) 125-141
12. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8 5 (2002) 1038-1044
13. Ibrahim N.K., Ellerhorst J.A., Theriault R.L., Rivera E., Esmaeli B., Soon-Shiong P., et al. Phase I study of cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel (ABI-007) in solid tumors. Clin Cancer Res 6 (2000) 571
14. Szente L., Vikmon M., Szeman J., and Otta K. Methyl-beta-cyclodextrin/paclitaxel aqueous solutions: a tool to test Cremophor-free paclitaxel. Stp Pharma Sci 9 3 (1999) 243-247
15. Bartoli H., Boitard M., Fessi H., Beriel H., Devissagnet J.P., Picot F., et al. In vitro and in vivo antitumoral activity of free and encapsulated taxol. J Microencapsulat 7 (1990) 191-197
16. Sharma A., and Straubinger R.M. Novel taxol formulations-preparation and characterization of taxol-containing liposomes. Pharmaceut Res 11 6 (1994) 889-896
17. Alkanonyuksel H., Ramakrishnan S., Chai H.B., and Pezzuto J.M. A mixed micellar formulation suitable for the parenteral administration of taxol. Pharmaceut Res 11 2 (1994) 206-212
18. Rodrigues M.L., Carter P., Wirth C., Mullins S., Lee A., and Blackburn B.K. Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug. Chem Biol 2 4 (1995) 223-227
19. Dosio F., Brusa P., Crosasso P., Arpicco S., and Cattel L. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J Controlled Rel 47 3 (1997) 293-304
20. Tarr B.D., Sambandan T.G., and Yalkowsky S.H. A new parenteral emulsion for the administration of taxol. Pharmaceut Res 4 2 (1987) 162-165
21. Greenwald R.B., Gilbert C.W., Pendri A., Conover C.D., Xia J., and Martinez A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem 39 2 (1996) 424-431
22. Sharma U.S., Balasubramanian S.V., and Straubinger R.M. Pharmaceutical and physical-properties of paclitaxel (taxol) complexes with cyclodextrins. J Pharmaceut Sci 84 10 (1995) 1223-1230
23. Demetrick J.S., Liggins R.T., Machan L., Davis N.L., Burt H.M., and Hunter W.L. The development of a novel intraperitoneal tumor-seeding prophylactic. Am J Surg 173 5 (1997) 403-406
24. Liggins R.T., D'Amours S., Demetrick J.S., Machan L.S., and Burt H.M. Paclitaxel loaded poly(l-lactic acid) microspheres for the prevention of intraperitoneal carcinomatosis after a surgical repair and tumor cell spill. Biomaterials 21 19 (2000) 1959-1969
25. Imola M.J., and Schramm V.L. Resorbable internal fixation in pediatric cranial base surgery. Laryngoscope 112 10 (2002) 1897-1901
26. Moe K.S., and Weisman R.A. Resorbable fixation in facial plastic and head and neck reconstructive surgery: an initial report on polylactic acid implants. Laryngoscope 111 10 (2001) 1697-1701
27. Damascelli B., Cantu G., Mattavelli F., Tamplenizza P., Bidoli P., Leo E., et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007)-Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92 10 (2001) 2592-2602
28. Hughes E.S.R., McDermott F.T., Polglase A.L., and Johnson W.R. Tumor recurrence in the abdominal-wall scar tissue after large-bowel cancer-surgery. Diseases Colon Rectum 26 9 (1983) 571-572
29. Liu J., Kraut E., Bender J., Brooks R., Balcerzak S., Grever M., et al. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemotherapy Pharmacol 49 5 (2002) 367-374
30. Gibson CR, Staubus AE, Barth RF, Yang WL, Kleinholz NM, Jones RB, et al. Boron neutron capture therapy of brain tumors: investigation of urinary metabolites and oxidation products of sodium borocaptate by electrospray ionization mass spectrometry. 2001 February;29(12):1588-98.
31. Au JLS, Li D, Gan YB, Gao X, Johnson AL, Johnston J, et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. 1998 May 15;58(10):2141-8.
32. Li D, Au JLS. Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect independent of drug efflux function of p-glycoprotein. 2001 July;18(7):907-13.
33. Audo I, Darjatmoko SR, Schlamp CL, Lokken JM, Lindstrom MJ, Albert DM, et al. Vitamin D analogues increase p53, p21, and apoptosis in a xenograft model of human retinoblastoma. 2003 October;44(10):4192-9.
34. McQuibban GA, Saurya S, Freeman M. Mitochondrial membrane remodelling regulated by a conserved rhomboid protease. 2003 May;423(6939):537-41.
35. Apodaca G, Bomsel M, Lindstedt R, Engel J, Frank D, Mostov KE, et al. Characterization of pseudomonas-aeruginosa-induced mdck cell injury-glycosylation-defective host-cells are resistant to bacterial killing. 1995 April;63(4):1541-51.
36. Saunders DE, Lawrence WD, Christensen C, Wappler NL, Ruan HM, Deppe G. Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. 1997 January;70(2):214-20.
37. Gan YB, Wientjes MG, Schuller DE, Au JLS. Pharmacodynamics of taxol in human head and neck tumors. 1996 May;56(9):2086-93.
38. Adler LM, Herzog TJ, Williams S, Rader JS, Mutch DG. Analysis of exposure times and dose-escalation of paclitaxel in ovarian-cancer cell-lines. 1994 October;74(7):1891-8.
39. 2 applications in the processing of polymers. Ind Eng Chem Res 42 25 (2003) 6431-6456
40. Guney O., and Akgerman A. Synthesis of controlled-release products in supercritical medium. AIChE J 48 4 (2002) 856-866
41. Kazarian S.G., and Martirosyan G.G. Spetroscopy of polymer/drug formulations processed with supercritical fluids: in situ ATR-IR and Raman study of impregnation of ibuprofen into PVP. Int J Pharmaceut 232 (2002) 81-90
42. Partridge K., Yang X., Clarke N.M.P., Okubo Y., Bessho K., Sebald W., et al. Adenoviral BMP-2 gene transfer in mesenchymal stem cells: in vitro and in vivo bone formation on biodegradable polymer scaffolds. Biochem Biophys Res Commun 292 1 (2002) 144-152
43. Woods H.M., Silva M.M.C.G., Nouvel C., Shakesheff K.M., and Howdle S.M. Materials processing in supercritical carbon dioxide: surfactants, polymers, and biomaterials. J Mater Chem 14 (2004) 1663-1678
44. Yang Y., Zeng C., and Lee L.J. Three-dimensional assembly of polymer microstructures at low temperatures. Adv Mater 16 6 (2004) 560-564
45. 2 (2003), Ohio State University, Columbus, OH
46. Liao X., Nawaby A.V., Whitfield P., Day M., Champagne M., and Denault J. Layered open pore poly(l-lactic acid) nanomorphology. Biomacromolecules 7 11 (2006) 2937-2941
47. Sato Y, Yamane M, Sorakubo A, Takishima S, Masuoka H. Solubility and diffusion coefficient of carbon dioxide in polylactide. In: The 21st Japan symposium on thermophysical properties, Nagoya, 2000. p. 196-8.
48. Marchetti P., Urien S., Cappellini G.A., Ronzino G., and Ficorella C. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 44 (2002) S3-S13
49. Ragazzi E., D'Ancona S., Berti E., and Carrara M. Cytotoxicity of paclitaxel in combination with cisplatin and a new Pt-mercaptopyridine complex. Anticancer Res 22 5 (2002) 2783-2788
50. Gueritte F. General and recent aspects of the chemistry and structure-activity relationships of taxoids. Curr Pharmaceut Des 7 13 (2001) 1229-1249
51. Matsuoka H., Furusawa M., Tomoda H., and Seo Y. Difference in cytotoxicity of paclitaxel against neoplastic and normal-cells. Anticancer Res 14 1A (1994) 163-167
52. Reichman B.S., Seidman A.D., Crown J.P.A., Heelan R., Hakes T.B., Lebwohl D.E., et al. Paclitaxel and recombinant human granulocyte-colony-stimulating factor as initial chemotherapy for metastatic breast-cancer. J Clin Oncol 11 10 (1993) 1943-1951
53. Dumitru S., and Dumitru M. Polymeric drug carriers. Polymeric biomaterials (1994), Marcel Dekker, New York
54. 2 sorption and dilation of poly(methyl methacrylate). Macromolecules 36 (1998) 472-478